RNASEL and prostate carcinoma: The specific Q variant of RNASEL with an almost threefold lower catalytic activity has been registered in about 13% of patients with carcinoma of the prostate, which may be accounted for by the increased risk of prostate cancer in about 50% in the case of heterozygous mutation, while its appearance in a homozygous form may increase the prostate cancer risk two times.